Conditions: Multiple Sclerosis
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 38
Healthy volunteers: yes

Brief summary:
The purpose of this trial is to evaluate the effects of Rebif® 44 mcg subcutaneous (sc) three times a week (tiw) on a) remyelination/demyelination, b) lesion and brain volume, c) central nervous system (CNS) iron deposition, and d) immune status in subjects with relapsing-remitting multiple sclerosis (RRMS) RRMS via several MRI techniques.

Detailed description:

Arms:
arm 1: Rebif 44 tiw arm 2: None

Interventions: intervention 1: Rebif
Intervention descriptions: intervention 1: 44 mcg tiw

Protocol document: